Vertex Pharmaceuticals Q4 2022 Financial Results & Pipeline Update

Vertex Pharmaceuticals presented its fourth quarter and full year 2022 financial results on February 7, 2023, highlighting pipeline progress across cystic fibrosis, sickle cell disease, pain management, and cell therapy programs. The company outlined expectations for five potential launches within five years and detailed development timelines for multiple clinical-stage candidates including exa-cel, VX-548, and VX-880. Key commercial initiatives included the targeted 2023 global launch of TRIKAFTA/KAFTRIO in younger CF patients and progress toward reaching all CF patients eligible for CFTR modulation therapy.